Spots Global Cancer Trial Database for childhood chronic myelogenous leukemia
Every month we try and update this database with for childhood chronic myelogenous leukemia cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
---|---|---|---|---|---|---|
Infusion of Off-the-Shelf Expanded Cord Blood Cells to Augment Cord Blood Transplant in Patients With Hematologic Malignancies | NCT01175785 | Accelerated Pha... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Previously Trea... Refractory Anem... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Myelo... | umbilical cord ... fludarabine pho... cyclophosphamid... ex vivo-expande... total-body irra... cyclosporine mycophenolate m... laboratory biom... | 6 Months - 45 Years | Nohla Therapeutics, Inc. | |
Biological Therapy in Treating Patients With Advanced Myelodysplastic Syndrome, Acute or Chronic Myeloid Leukemia, or Acute Lymphoblastic Leukemia Who Are Undergoing Stem Cell Transplantation | NCT00052520 | Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... B-cell Adult Ac... B-cell Childhoo... Childhood Chron... Childhood Myelo... Chronic Myelomo... Essential Throm... Polycythemia Ve... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Refractory Anem... Refractory Anem... Relapsing Chron... Secondary Acute... T-cell Adult Ac... T-cell Childhoo... | therapeutic all... aldesleukin peripheral bloo... allogeneic bone... laboratory biom... gene expression... immunologic tec... flow cytometry polymerase chai... cytogenetic ana... staining method | - | Fred Hutchinson Cancer Center | |
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
STI571 in Treating Patients With Recurrent Leukemia | NCT00004932 | Leukemia | imatinib mesyla... | - 21 Years | Children's Oncology Group | |
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
Busulfan, Antithymocyte Globulin, and Fludarabine Followed By a Donor Stem Cell Transplant in Treating Young Patients With Blood Disorders, Bone Marrow Disorders, Chronic Myelogenous Leukemia in First Chronic Phase, or Acute Myeloid Leukemia in First Remission | NCT00305708 | Congenital Ameg... Diamond-blackfa... Fanconi Anemia Leukemia Severe Congenit... Thrombocytopeni... | anti-thymocyte ... busulfan fludarabine pho... allogeneic bone... peripheral bloo... umbilical cord ... radiation thera... | - 17 Years | University of California, San Francisco | |
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
Chemotherapy and Total-Body Irradiation Followed by Donor Umbilical Cord Blood Transplant, Cyclosporine, and Mycophenolate Mofetil in Treating Patients With Hematologic Cancer | NCT00290641 | Chronic Myelopr... Leukemia Lymphoma Myelodysplastic... | filgrastim graft-versus-tu... cyclophosphamid... cyclosporine fludarabine pho... mycophenolate m... umbilical cord ... radiation thera... | - 45 Years | Masonic Cancer Center, University of Minnesota | |
Donor Peripheral Stem Cell Transplant and Donor Natural Killer Cell Transplant After Total-Body Irradiation, Thiotepa, Fludarabine, and Muromonab-CD3 in Treating Patients With Leukemia or Other Blood Diseases | NCT00450983 | Graft Versus Ho... Leukemia Myelodysplastic... | muromonab-CD3 natural killer ... fludarabine pho... methotrexate thiotepa gene expression... flow cytometry immunologic tec... allogeneic hema... in vitro-treate... total-body irra... | - 45 Years | Fred Hutchinson Cancer Center | |
Chemotherapy, Interferon, and Bone Marrow Transplantation in Treating Patients With Chronic Myelogenous Leukemia | NCT00002771 | Leukemia | recombinant int... busulfan cytarabine hydroxyurea idarubicin allogeneic bone... autologous bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00045422 | Leukemia | recombinant int... imatinib mesyla... | - | Memorial Sloan Kettering Cancer Center | |
Quality of Life of Adult Cancer Survivors Who Have Undergone a Previous Bone Marrow or Peripheral Stem Cell Transplant for a Childhood Hematologic Cancer | NCT00126477 | Leukemia Lymphoma Myelodysplastic... Quality of Life | cognitive asses... management of t... psychosocial as... quality-of-life... | 18 Years - | Fred Hutchinson Cancer Center | |
Imatinib Mesylate After a Donor Stem Cell Transplant in Treating Patients With Philadelphia Chromosome-Positive Leukemia | NCT00244829 | Leukemia | imatinib mesyla... adjuvant therap... | - | Fred Hutchinson Cancer Center | |
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
Imatinib Mesylate and Decitabine in Treating Patients With Chronic Myelogenous Leukemia | NCT00054431 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Relapsing Chron... | imatinib mesyla... decitabine laboratory biom... | - | National Cancer Institute (NCI) | |
Donor Stem Cell Transplant in Treating Young Patients With Myelodysplastic Syndrome, Leukemia, Bone Marrow Failure Syndrome, or Severe Immunodeficiency Disease | NCT00295971 | Congenital Ameg... Leukemia Myelodysplastic... Severe Congenit... | anti-thymocyte ... therapeutic all... fludarabine pho... thiotepa allogeneic bone... allogeneic hema... in vitro-treate... total-body irra... | 1 Year - 17 Years | University of California, San Francisco | |
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00045422 | Leukemia | recombinant int... imatinib mesyla... | - | Memorial Sloan Kettering Cancer Center | |
Donor Umbilical Cord Blood Transplant By Injection Into the Bone Marrow in Treating Patients With Hematologic Cancer | NCT00295880 | Myeloproliferat... Leukemia Lymphoma Myelodysplastic... | umbilical cord ... | 12 Years - 45 Years | Masonic Cancer Center, University of Minnesota | |
Flu,Alemtuzumab,and TBI Followed By Donor Stem Cell Chronic Phase CML | NCT00416884 | Leukemia | Campath Fludarabine Total Body Irra... T-Cell Deplete | 4 Years - 75 Years | OHSU Knight Cancer Institute | |
Therapeutic Allogeneic Lymphocytes and Aldesleukin in Treating Patients With High-Risk or Recurrent Myeloid Leukemia After Undergoing Donor Stem Cell Transplant | NCT00052598 | Accelerated Pha... Acute Myeloid L... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Chron... Childhood Myelo... Recurrent Adult... Recurrent Child... Relapsing Chron... Secondary Acute... | therapeutic all... aldesleukin laboratory biom... flow cytometry | - | Fred Hutchinson Cancer Center | |
Tipifarnib in Treating Young Patients With Refractory Leukemia | NCT00022451 | Leukemia | tipifarnib | - 21 Years | National Institutes of Health Clinical Center (CC) | |
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center | |
Chemotherapy and a Donor Natural Killer Cell Infusion in Treating Patients With Relapsed or Persistent Leukemia or Myelodysplastic Syndrome After a Donor Stem Cell Transplant | NCT00526292 | Leukemia Myelodysplastic... | natural killer ... cyclophosphamid... fludarabine | - 120 Years | Memorial Sloan Kettering Cancer Center | |
Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00030394 | Childhood Chron... Chronic Myeloge... Chronic Phase C... | imatinib mesyla... laboratory biom... pharmacological... | - 21 Years | National Cancer Institute (NCI) | |
Imatinib Mesylate With or Without Interferon Alfa or Cytarabine Compared With Interferon Alfa Followed by Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia | NCT00055874 | Leukemia | recombinant int... cytarabine hydroxyurea imatinib mesyla... allogeneic bone... autologous bone... peripheral bloo... | 18 Years - 120 Years | Heidelberg University | |
Study of Metabolic Syndrome in Adolescent and Young Adult Survivors of Childhood Leukemia Who Have Undergone Stem Cell Transplant | NCT00920842 | Cardiovascular ... Leukemia Long-term Effec... Metabolic Syndr... | 9 Years - 21 Years | Fred Hutchinson Cancer Center | ||
Safety Study of Human Myeloid Progenitor Cells (CLT-008) After Cord Blood Transplant for Hematologic Malignancy | NCT00891137 | Leukemia Lymphoma Multiple Myelom... Plasma Cell Neo... Myelodysplastic... | human myeloid p... | 12 Years - 65 Years | Cellerant Therapeutics | |
Chemotherapy and Biological Therapy With or Without Bone Marrow or Peripheral Stem Cell Transplant in Treating Patients With Chronic Myelogenous Leukemia | NCT00025402 | Leukemia | filgrastim recombinant int... busulfan cyclophosphamid... cytarabine etoposide hydroxyurea idarubicin allogeneic bone... peripheral bloo... radiation thera... | - | National Cancer Institute (NCI) | |
FR901228 in Treating Children With Refractory or Recurrent Solid Tumors or Leukemia | NCT00053963 | Blastic Phase C... Childhood Centr... Childhood Choro... Childhood Chron... Childhood Crani... Childhood Grade... Childhood Grade... Childhood Grade... Childhood High-... Childhood Infra... Childhood Low-g... Childhood Spina... Childhood Supra... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Recurrent Child... Refractory Chro... Relapsing Chron... Unspecified Chi... | romidepsin | - 21 Years | National Cancer Institute (NCI) | |
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
Donor Bone Marrow Transplant With or Without G-CSF in Treating Young Patients With Hematologic Cancer or Other Diseases | NCT00450450 | Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Phase C... de Novo Myelody... Juvenile Myelom... Previously Trea... Recurrent Child... Secondary Myelo... | allogeneic bone... laboratory biom... filgrastim | - 21 Years | Children's Oncology Group | |
Treosulfan, Fludarabine Phosphate, and Total-Body Irradiation Before Donor Stem Cell Transplant in Treating Patients With High-Risk Acute Myeloid Leukemia, Myelodysplastic Syndrome, Acute Lymphoblastic Leukemia | NCT00860574 | Accelerated Pha... Adult Acute Lym... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Adult Acute Mye... Blastic Phase C... Childhood Acute... Childhood Acute... Childhood Chron... Childhood Myelo... Chronic Myelomo... de Novo Myelody... Previously Trea... Recurrent Adult... Recurrent Adult... Recurrent Child... Recurrent Child... Secondary Myelo... Untreated Adult... Untreated Child... | treosulfan fludarabine pho... total-body irra... peripheral bloo... tacrolimus allogeneic bone... allogeneic hema... methotrexate | - 60 Years | Fred Hutchinson Cancer Center | |
Dasatinib in Treating Young Patients With Recurrent or Refractory Solid Tumors or Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia or Chronic Myelogenous Leukemia That Did Not Respond to Imatinib Mesylate | NCT00316953 | Accelerated Pha... Blastic Phase C... Childhood Chron... Chronic Myeloge... Meningeal Chron... Recurrent Child... Relapsing Chron... Unspecified Chi... | dasatinib pharmacological... laboratory biom... | 1 Year - 21 Years | National Cancer Institute (NCI) | |
Chemotherapy and Peripheral Stem Cell Transplantation Followed by Immunotherapy in Treating Patients With Chronic Myelogenous Leukemia | NCT00003727 | Leukemia | filgrastim recombinant int... sargramostim therapeutic aut... carmustine cyclophosphamid... etoposide gemcitabine hyd... melphalan bone marrow abl... in vitro-treate... | - 120 Years | University of Maryland, Baltimore | |
Decision Making About Participating in Pharmacokinetic Studies in Patients Enrolled in a Phase I Treatment Clinical Trial | NCT00890435 | Brain and Centr... Leukemia Unspecified Adu... Unspecified Chi... | questionnaire a... psychosocial as... | 18 Years - | Children's Oncology Group | |
Interferon Alfa and Imatinib Mesylate in Treating Patients With Chronic Myelogenous Leukemia | NCT00045422 | Leukemia | recombinant int... imatinib mesyla... | - | Memorial Sloan Kettering Cancer Center | |
Donor Stem Cell Transplant in Treating Patients With Myeloid Cancer or Other Disease | NCT00392782 | Leukemia Myelodysplastic... | anti-thymocyte ... fludarabine pho... thiotepa peripheral bloo... total-body irra... | - 60 Years | Masonic Cancer Center, University of Minnesota | |
Total-Body Irradiation, Thiotepa, and Fludarabine in Treating Young Patients Who Are Undergoing a Donor Stem Cell Transplant for Hematologic Cancer | NCT00112567 | Leukemia Myelodysplastic... | fludarabine pho... thiotepa peripheral bloo... radiation thera... | - 20 Years | Fred Hutchinson Cancer Center |